PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology
Article excerpt
Highlighted: the sentence this signal was extracted from
AbbVie Ventures and Lumination Capital joining existing lead investors Samsara BioCapital and Lightstone Ventures Financing supports TNFα development candidate nomination and initiation of IND-enabling studies, alongside advancement of oral TL1A inhibitors into lead optimization Proprietary QUAISAR platform, combined with approach to Physical AI, continues to drive rapid design of optimized oral drug candidates WATERTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PsiThera, a biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases, today announced the closing of a $25 million financing. New investors AbbVie Ventures and Lumination Capital participated, along with existing lead investors Samsara BioCapital and Lightstone Ventures, and other existing investors. In connection with the financing, Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, has joined PsiThera's Board of Directors. Proceeds from the financing are expected to fund operations, supporting development candidate nomination and the initiation of IND-enabling studies for the company's lead oral small molecule TNFα inhibitor, as well as advancement of its oral TL1A program into lead optimization. The company's proprietary QUAISAR platform combines physics-based molecular simulation, machine...
Keep reading with a free account
The rest of this article, and every signal for AbbVie, is in your free account.